Coexistence of neuroleptic malignant syndrome and a hyperosmolar hyperglycemic state

Yang, Chung-Wei; Lu, Ching Liang; Wu, Chih‐Cheng; Wen, Szu-Chi

doi:10.1016/j.ajem.2011.02.031

The American Journal of Emergency Medicine

2012

DOI: 10.1016/j.ajem.2011.02.031

|View full text |Cite

Coexistence of neuroleptic malignant syndrome and a hyperosmolar hyperglycemic state

Chung-Wei Yang

Ching Liang Lu

Chih‐Cheng Wu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study confirmed that neuroleptic syndrome results from the use of such antipsychotics. Patients suffering from schizophrenia and psychosis are usually given the same drug, albeit in different doses21 .In a literature review, Croarkin et al 4 sought to determine whether the symptoms are exhibited differently or not depending on one's age. The information obtained was limited to patients below 18 years.…”

mentioning

confidence: 99%

Neuroleptic syndrome among patients receiving antipsychotic drugs-review

Yuabova

2016

J Surg Clin Res

View full text Add to dashboard Cite

Neuroleptic Malignant Syndrome is occasional but deadly reaction, which results from treatment with antipsychotic medications. Risk aspects include the following: dehydration, agitation, and history of neuroleptic malignant syndrome. Despite the fact that Neuroleptic Malignant Syndrome has been described as adverse effect from treatment with antipsychotic medications, patients suffering with chemical imbalance of brain or mood disorders, especially when treated with lithium, fall in to higher risk group. Standard criteria for the diagnosis of Neuroleptic Malignant Syndrome highlight the following signs and symptoms: muscle rigidity, hyperthermia, alteration in mental status, and autonomic dysfunction. Syndrome usually lasts from 7 to 10 days in simple and uncomplicated patients who receiving neuroleptics orally. Early detection and diagnosis of syndrome are up the most importance, where discontinuance of triggering medication, managing of fluid balance, control of body temperature and close observation for complications takes place. Use of dopamine agonists should be advised in more complex cases. Electroconvulsive therapy has also been effective in a few cases. In this article author reviews the proposed pathology, symptoms, complications, and treatment of Neuroleptic malignant syndrome.

show abstract

mentioning

confidence: 99%

Neuroleptic syndrome among patients receiving antipsychotic drugs-review

Yuabova

2016

J Surg Clin Res

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Coexistence of neuroleptic malignant syndrome and a hyperosmolar hyperglycemic state

Cited by 1 publication

References 15 publications

Neuroleptic syndrome among patients receiving antipsychotic drugs-review

Neuroleptic syndrome among patients receiving antipsychotic drugs-review

Contact Info

Product

Resources

About